肺癌基因組檢測藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按技術、樣本類型、檢測組類型、最終用戶、地區和競爭格局分類，2020-2030年預測

全球肺癌基因組檢測市場規模預計將從2024年的19億美元成長至2030年的25.9億美元，複合年成長率（CAGR）為5.30%。肺癌基因組檢測涵蓋腫瘤脫氧核糖核酸（DNA）的分析，旨在識別特定的基因突變或改變，從而為患者選擇個人化的治療策略。市場成長的主要促進因素包括全球肺癌發生率的上升、基因組定序技術（例如新一代定序）的不斷進步，以及腫瘤學領域對精準醫療方法日益成長的需求。

主要市場促進因素

全球肺癌基因組檢測藥物市場受到全球肺癌發生率不斷上升的顯著影響。日益加重的疾病負擔使得人們迫切需要先進的診斷工具，以進行精準的患者分層並指導標靶治療介入。

主要市場挑戰

先進基因組檢測的高昂成本嚴重阻礙了全球肺癌基因組檢測藥物市場的成長。高昂的檢測費用直接限制了病患的就醫途徑，尤其是在醫療系統面臨預算限制或尚未建立完善的報銷機制的情況下。

主要市場趨勢

人工智慧和機器學習顯著提升了肺癌基因組解讀能力，並提高了複雜資料分析的速度和準確性。這些技術能夠精準識別對標靶治療至關重要的可操作突變。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球肺癌基因組檢測藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依技術分類（聚合酶鍊式反應、次世代定序、螢光原位雜合技術、其他）
  • 依樣本類型（組織切片、液體切片）
  • 依檢測組類型（多基因檢測組、單基因檢測組）
  • 按最終使用者（研究機構、醫院和診所、診斷實驗室、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美肺癌基因組檢測藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲肺癌基因組檢測藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區肺癌基因組檢測藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲肺癌基因組檢測藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲肺癌基因組檢測藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球肺癌基因組檢測藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE NV
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

第16章：策略建議

第17章調查會社について,免責事項

The Global Lung Cancer Genomic Testing Medicine Market will grow from USD 1.90 Billion in 2024 to USD 2.59 Billion by 2030 at a 5.30% CAGR. Lung cancer genomic testing medicine encompasses the analysis of tumor deoxyribonucleic acid to identify specific genetic mutations or alterations, enabling the selection of personalized therapeutic strategies for patients. The market's growth is primarily driven by the rising global incidence of lung cancer, continuous advancements in genomic sequencing technologies such as Next-Generation Sequencing, and an increasing imperative for precision medicine approaches in oncology.

Key Market Drivers

The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities.

Key Market Challenges

The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.

Key Market Trends

Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed.

Key Market Players

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Medicine Market, By Technology:

• Polymerase Chain Reaction
• Next-Generation Sequencing
• Fluorescence In-Situ Hybridization
• Others

Lung Cancer Genomic Testing Medicine Market, By Sample Type:

• Tissue Biopsy
• Liquid Biopsy

Lung Cancer Genomic Testing Medicine Market, By Panel Type:

• Multi-Gene Panel
• Single-Gene Panel

Lung Cancer Genomic Testing Medicine Market, By End-User:

• Research Organization
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Lung Cancer Genomic Testing Medicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Others)
  • 5.2.2. By Sample Type (Tissue Biopsy, Liquid Biopsy)
  • 5.2.3. By Panel Type (Multi-Gene Panel, Single-Gene Panel)
  • 5.2.4. By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Lung Cancer Genomic Testing Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Sample Type
  • 6.2.3. By Panel Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Panel Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Panel Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Panel Type
      • 6.3.3.2.4. By End-User

7. Europe Lung Cancer Genomic Testing Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Sample Type
  • 7.2.3. By Panel Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Panel Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Panel Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Panel Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Panel Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Panel Type
      • 7.3.5.2.4. By End-User

8. Asia Pacific Lung Cancer Genomic Testing Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Sample Type
  • 8.2.3. By Panel Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Panel Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Panel Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Panel Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Panel Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Panel Type
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Lung Cancer Genomic Testing Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Sample Type
  • 9.2.3. By Panel Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Panel Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Panel Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Panel Type
      • 9.3.3.2.4. By End-User

10. South America Lung Cancer Genomic Testing Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Sample Type
  • 10.2.3. By Panel Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Panel Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Panel Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Panel Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN NV
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Quest Diagnostics Incorporated
• 15.5. Laboratory Corporation of America Holdings
• 15.6. CENTOGENE N.V.
• 15.7. BGI Genomics Co. Ltd.
• 15.8. CeGaT GmbH
• 15.9. Illumina Inc.
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer